c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells

被引:48
|
作者
Chai, YL [1 ]
Chipitsyna, G [1 ]
Cui, JQ [1 ]
Liao, BS [1 ]
Liu, S [1 ]
Aysola, K [1 ]
Yezdani, M [1 ]
Reddy, ESP [1 ]
Rao, VN [1 ]
机构
[1] Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, Philadelphia, PA 19102 USA
关键词
c-Fos; BRCA1/BRCA1a/1b; Elk-1; growth suppression; breast cancer; protein-protein interaction;
D O I
10.1038/sj.onc.1204256
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain family of transcriptional factors, plays an important role in the induction of immediate early gene expression in response to a variety of extracellular signals. In this study, we demonstrate for the first time the in, vitro and in vivo interaction of Elk-1 with BRCA1 splice variants BRCA1a and BRCA1b using GST-pull down assays, co-imunoprecipitations/Western blot analysis of cell extracts from breast cancer cells and mammalian two-hybrid assays. We have localized the BRCA1 interaction domain of Elk-1 protein to the conserved ETS domain, a motif involved in DNA binding and protein-protein interactions. We also observed binding of BRCA1 proteins to other ETS-domain transcription factors SAP1, ETS-1, ERG-2 and Fli-1 but not to Elk-1 splice variant Delta Elk-1 and c-Fos protooncogene, Both BRCA1a and BRCA1b splice variants function as growth suppressors of human breast cancer cells. interestingly, our studies reveal that although both Elk-1 and SAP-1 are highly homologous members of a subfamily of ETS domain proteins called ternary complex factors, it is only Elk-1 but not SAP-I that can augment the growth suppressive function of BRCA1a/1b proteins in breast cancer cells, Thus Elk-1 could be a potential downstream target of BRCA1 in its growth control pathway, Furthermore, we hare observed inhibition of c-Fos promoter activity in BRCA1a transfected stable breast cancer cells and over expression of BRCA1a/1b attenuates MEK-induced SRE activation in vivo. These results demonstrate for the first time a link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 protein, All these results taken together suggest that one of the mechanisms by which BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos.
引用
收藏
页码:1357 / 1367
页数:11
相关论文
共 50 条
  • [1] c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells
    YuLi Chai
    Galina Chipitsyna
    Jianqi Cui
    Boshan Liao
    Shuang Liu
    Kartik Aysola
    Mona Yezdani
    E Shyam P Reddy
    Veena N Rao
    Oncogene, 2001, 20 : 1357 - 1367
  • [2] Mitochondrial Localization, ELK-1 Transcriptional Regulation and Growth Inhibitory Functions of BRCA1, BRCA1a, and BRCA1b proteins
    Maniccia, Anna W.
    Lewis, Catherine
    Begum, Nurjahan
    Xu, Jingyao
    Cui, Jianqi
    Chipitsyna, Galina
    Aysola, Kartik
    Reddy, Vaishali
    Bhat, Ganapathy
    Fujimura, Yasuo
    Henderson, Beric
    Reddy, E. Shyam P.
    Rao, Veena N.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2009, 219 (03) : 634 - 641
  • [3] Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b
    Cui, JQ
    Wang, HC
    Reddy, ESP
    Rao, VN
    ONCOLOGY REPORTS, 1998, 5 (03) : 585 - 589
  • [4] BRCA1: linking HOX to breast cancer suppression
    Kideok Jin
    Saraswati Sukumar
    Breast Cancer Research, 12
  • [5] Epigenetic regulation of BRCA1 in breast cancer cells
    Tartaglia, Jaxon
    Delgado-Cruzata, Lissette
    Duran, Lisset
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (03) : S485 - S486
  • [6] Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants
    Ruiz de Garibay, Gorka
    Fernandez-Garcia, Ignacio
    Mazoyer, Sylvie
    de Calais, Flavia Leme
    Ameri, Pietro
    Vijayakumar, Sangeetha
    Martinez-Ruiz, Haydeliz
    Damiola, Francesca
    Barjhoux, Laure
    Thomassen, Mads
    Andersen, Lars v B.
    Herranz, Carmen
    Mateo, Francesca
    Palomero, Luis
    Espin, Roderic
    Gomez, Antonio
    Garcia, Nadia
    Jimenez, Daniel
    Bonifaci, Nuria
    Extremera, Ana, I
    Castano, Julio
    Raya, Angel
    Eyras, Eduardo
    Puente, Xose S.
    Brunet, Joan
    Lazaro, Conxi
    Radice, Paolo
    Barnes, Daniel R.
    Antoniou, Antonis C.
    Spurdle, Amanda B.
    de la Hoya, Miguel
    Baralle, Diana
    Barcellos-Hoff, Mary Helen
    Pujana, Miquel A.
    HUMAN MUTATION, 2021, 42 (11) : 1488 - 1502
  • [7] Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
    Ferreyra, Yomali
    Rosas, Gina
    Cock-Rada, Alicia M.
    Araujo, Jhajaira
    Bravo, Leny
    Doimi, Franco
    Casas, Jhoysi
    Clavo, Maria de los Angeles
    Pinto, Joseph A.
    Belmar-Lopez, Carolina
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] CLINICOPATHOLOGICAL CHARACTERISTICS AND BRCA1 /BRCA2 PATHOGENIC VARIANTS OF PATIENTS WITH BREAST CANCER
    Eras, Nazan
    Tuncel, Ferah
    Altintas, Zuhal
    Erden, Sema
    POLISH JOURNAL OF PATHOLOGY, 2024, 75 (01) : 1 - 7
  • [9] Exploring genetic variants of BRCA1 and BRCA2 in Indian Breast Cancer cases
    Ray, Manisha
    Banik, Suranjana
    Dash, Shilpi Samikshya
    Sable, Mukund Namdev
    HUMAN GENE, 2022, 34
  • [10] Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status
    Jane C. Figueiredo
    Jennifer D. Brooks
    David V. Conti
    Jenny N. Poynter
    Sharon N. Teraoka
    Kathleen E. Malone
    Leslie Bernstein
    Won D. Lee
    David J. Duggan
    Ashley Siniard
    Patrick Concannon
    Marinela Capanu
    Charles F. Lynch
    Jørgen H. Olsen
    Robert W. Haile
    Jonine L. Bernstein
    Breast Cancer Research and Treatment, 2011, 127 : 819 - 829